These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36455483)

  • 21. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
    Dieudonné AS; Lambrechts D; Smeets D; Belmans A; Wildiers H; Paridaens R; Hyonil C; Timmerman D; Christiaens MR; Vergote I; Neven P
    Ann Oncol; 2014 Jan; 25(1):90-5. PubMed ID: 24265353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
    Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
    Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
    Dehal SS; Kupfer D
    Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues.
    Abdellatif KR; Belal A; Omar HA
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4960-3. PubMed ID: 23860592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
    Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
    Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
    Watanabe M; Watanabe N; Maruyama S; Kawashiro T
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells.
    Gundimeda U; Chen ZH; Gopalakrishna R
    J Biol Chem; 1996 Jun; 271(23):13504-14. PubMed ID: 8662863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
    Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
    Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
    Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Dohollou N; Bernard-Marty C; Laharie-Mineur H; Filleron T; Roché H; Chatelut E; Thomas F; White-Koning M
    Clin Pharmacol Ther; 2021 May; 109(5):1244-1255. PubMed ID: 33047329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
    Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
    Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
    Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines.
    Vessières A; Corbet C; Heldt JM; Lories N; Jouy N; Laïos I; Leclercq G; Jaouen G; Toillon RA
    J Inorg Biochem; 2010 May; 104(5):503-11. PubMed ID: 20116857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
    Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
    PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.